Lyell Immunopharma Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: Lyell Immunopharma Inc.
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 2834 — Pharmaceutical Preparations
Jurisdiction of incorporation: Delaware
Headquarters city: South SAN Francisco
Headquarters state / province: California
Headquarters country: United States
Fiscal year end: December
Ticker symbol: LYEL
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001806952
EIN: 83-3006753

Board of directors

Follow this board

Cathy Friedman · Director
Since 2023
Elizabeth G. Nabel · Director
Since 2023
Hans Edgar Bishop · Director
Since 2023
Lynn Seely · Director · President and CEO
Since 2023
Mark Bachleda · Director
Since 2025
Otis W. Brawley · Director
Since 2023
Richard Klausner · Director
Since 2023
Robert Nelsen · Director Overboarded
Since 2023
Sumant Ramachandra · Director
Since 2024
William Jl Rieflin · Director
Since 2023

Chief executives

Lynn Seely · President and CEO

Dates unknown

Director election results

Annual meeting of June 10, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

8 of this board's directors also sit on 14 other boards. 12 are in the same sector.

Shared director Other board Same sector

Agilent Technologies Inc.
via Hans Edgar Bishop and Otis W. Brawley
Sana Biotechnology Inc. Same sector
via Hans Edgar Bishop and Robert Nelsen
AbCellera Biologics Inc. Same sector
via Lynn Seely
City Therapeutics Inc. Same sector
via Robert Nelsen
Incyte Corp. Same sector
via Otis W. Brawley
Kardigan Inc. Same sector
via Robert Nelsen
Lycia Therapeutics Inc. Same sector
via William Jl Rieflin
Medtronic plc. Same sector
via Elizabeth G. Nabel
Moderna Inc. Same sector
via Elizabeth G. Nabel
PDS Biotechnology Corporation Same sector
via Otis W. Brawley
Parabilis Medicines Inc. Same sector
via Richard Klausner
Prime Medicine Inc. Same sector
via Robert Nelsen
Seer Inc.
via Cathy Friedman
Vir Biotechnology Inc. Same sector
via Robert Nelsen

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $74,999,953; 4 purchases by 4 insiders
Sold, last 12 months: $593,981; 25 sales by 7 insiders

Date	Insider	Transaction	Shares	Price	Value
Nov 4, 2026	ARCH Venture Partners IX, LLC 10% owner	Open-market purchase	+2,321,262	$10.77	$24,999,992
Nov 4, 2026	ARCH Venture Fund XIII, L.P. 10% owner	Open-market purchase	+2,321,262	$10.77	$24,999,992
Oct 12, 2026	Aguirre Jarrad Mattieu Officer (Chief Medical Officer)	Open-market sale	−422	$8.63	$3,642
Sep 10, 2026	Shook David Officer (Chief Medical Officer)	Open-market sale	−500	$12.70	$6,350
Aug 21, 2026	Hill Stephen J. Officer (Chief Operating Officer)	Open-market sale	−989	$15.54	$15,369
Aug 21, 2026	Lee Gary K. Officer (Chief Scientific Officer)	Open-market sale	−1,457	$15.54	$22,642
Aug 21, 2026	Lynn Seely Director, Officer (President and CEO)	Open-market sale	−9,589	$15.54	$149,013
Aug 10, 2026	Bulis Veronica Sanchez Officer (VP, Corporate Controller)	Open-market sale	−621	$14.34	$8,905
Aug 10, 2026	Hill Stephen J. Officer (Chief Operating Officer)	Open-market sale	−89	$14.34	$1,276
Aug 10, 2026	Lee Gary K. Officer (Chief Scientific Officer)	Open-market sale	−131	$14.34	$1,879
Aug 10, 2026	Lynn Seely Director, Officer (President and CEO)	Open-market sale	−390	$14.34	$5,593
Jul 27, 2026	Innovative Cellular Therapeutics Holdings Ltd 10% owner	Other	−38,500	—	—
Jul 27, 2026	Innovative Cellular Therapeutics Holdings Ltd 10% owner	Other	−44,000	—	—
Jul 17, 2026	Innovative Cellular Therapeutics Holdings Ltd 10% owner	Open-market sale	−10	$13.70	$137
Jul 16, 2026	Innovative Cellular Therapeutics Holdings Ltd 10% owner	Open-market sale	−10	$13.73	$137

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

3M Company NYSE: MMM · ST Paul, United States Organization ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States Organization ACADIA Pharmaceuticals Inc. Nasdaq: ACAD · SAN Diego, United States Organization ADMA Biologics Inc Nasdaq: ADMA · Ramsey, United States Organization

Questions about Lyell Immunopharma Inc.

Who is the CEO of Lyell Immunopharma Inc.?

Lynn Seely is Lyell Immunopharma Inc.'s President and CEO.

How many directors are on Lyell Immunopharma Inc.'s board?

Lyell Immunopharma Inc.'s board has 10 directors: Cathy Friedman, Elizabeth G. Nabel, Hans Edgar Bishop, Lynn Seely, Mark Bachleda, Otis W. Brawley, Richard Klausner, Robert Nelsen, Sumant Ramachandra and William Jl Rieflin.

Are Lyell Immunopharma Inc. insiders buying or selling shares?

Over the last 12 months, Lyell Immunopharma Inc. insiders bought $75.0 million of shares in 4 purchases and sold $593,981 of shares in 25 sales on the open market, as reported to the SEC on Forms 4 and 5.

How is Lyell Immunopharma Inc. connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="lyell-immunopharma-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.